The Organ Transplant Problem

You can’t drop innovation into a culture that rejected innovation. It’s an organ transplant into a body primed to reject it. The antibodies don’t know they’re killing the patient. They’re doing their job.

I’ve lived this from the inside. Three of my companies were acquired, and I ran a division inside an acquirer afterward, so I’ve seen the cycle from both ends: the company that buys innovation because it can no longer make its own, and the machinery that then destroys what it bought. The pattern is so consistent it deserves a name, and the transplant metaphor is the right one because it locates the problem correctly. The failure isn’t malice and it isn’t stupidity. It’s an immune response.

The sequence runs like this. A company achieves dominance, and the qualities that got it there, product obsession, tolerance for weird bets, atrophy, because they’re no longer what gets rewarded. Steve Jobs diagnosed it in the Lost Interview: the product people get driven out and the sales people become the heroes, because when you have a monopoly on distribution, sales is where the numbers come from. Eventually leadership notices the innovation is gone and does the rational-seeming thing. They buy some.

And then the antibodies attack, each one doing its job. The sales org can’t sell what it doesn’t understand, so it doesn’t, and the acquired product’s numbers disappoint. The acquired team’s decision speed collides with the acquirer’s process, and process wins, because process is how a big company protects itself from its own size. The original founders hit their retention cliffs and leave, taking the vision with them. The product atrophies. Three years later someone writes it down as a failed bet, and the cycle often resets with the next acquisition. I don’t think the people in that loop are learning nothing on purpose. The org’s incentives make the lesson hard to keep.

What would it take to break the cycle? The honest answers are all expensive, which is the point. Restructure incentives so the acquired thing counts in the numbers that decide careers. Protect the team from integration instead of celebrating integration, and accept losing some of your own people who resent the special treatment. Have leadership show up personally, not quarterly, because the org reads attention as a signal of what’s safe to attack. Most acquirers won’t pay those costs, not because the people running them are careless, but because the costs collide with how the larger company already works. I’ve been on both sides of that collision. Knowing the pattern doesn’t make it easy to stop.

The cheaper alternative is upstream: keep the product culture alive so you never have to shop for one. Easy to say. And nearly every company that gets big enough fails to do it, which suggests the failure is structural rather than a sequence of individual mistakes. If it were only a mistake, someone would have stopped making it by now.

Which leads to the uncomfortable ending, and I’d rather leave it uncomfortable than resolve it falsely. If the immune response is structural, then buying innovation may be a category error, like buying fitness. The acquisition delivers the artifact, the product, the team, the roadmap, and not the capability that produced them, and the capability was the thing you needed. What that implies about the entire acquisition-driven model of corporate renewal, an economy’s worth of companies buying what they can no longer make, from companies that will now stop making it, is a question I’ve decided not to answer on the way out.